Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib
Identifying ADR predictors is essential for personalizing treatment strategies. Both pirfenidone and nintedanib are crucial in managing IPF, highlighting the need for further research to optimize personalized therapies and patient outcomes.
Authors
- Alessio Provenzani (ORCID: https://orcid.org/0000-0001-7132-000X)
- Patrizio Vitulo (ORCID: https://orcid.org/0000-0003-1699-0208)
- Piera Polidori (ORCID: https://orcid.org/0000-0001-8496-9908)
- Daniele Leonardi Vinci (ORCID: https://orcid.org/0000-0003-4383-3726)
- R. Di Stefano
- Gaetano Floridia
- Anna Carollo (ORCID: https://orcid.org/0009-0008-1931-8330)
- Adriana Callari
- Miriam Alaimo
- Salvatore Di Maria (ORCID: https://orcid.org/0000-0001-6890-6587)
- Fabio Tuzzolino (ORCID: https://orcid.org/0000-0003-2058-2135)
Institutions
- University of Messina (IT)
- University of Catania (IT)
- Ospedale Vincenzo Cervello (IT)
- Data Management (Italy) (IT)
- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IT)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1177/20420986251341645
- Citations
- 5
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Agenzia Italiana del Farmaco, Ministero della Salute